In the current economic environment companies are faced with increased pressure to manage cash and meet investor expectations with tightened budgets. Life science industry CFOs, as a recent survey and…
After considerable government pressure to reduce insulin costs in the US, Eli Lilly recently slashed its prices by as much as 70 percent, followed by competitors Novo Nordisk and Sanofi.…
A roundup of some of the biggest pharma and biotech news from China including the collaboration between Elektr and Sinopharm; Biocytogen’s partnership with Janssen and deal with Chipscreen Biosciences; China’s…
A roundup of the latest pharma news from the United Arab Emirates (UAE) including Julpher’s pursuit of its growth strategy with a new CEO, Global Pharma’s tech transfer deal with…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
In the largest pharma acquisition in four years, Pfizer has picked up oncology biotech Seagen for USD 43 billion. The deal, which could signal a rebound in M&A activity as…
The latest news from the Indian pharma industry, including Dr. Reddy’s purchase of Mayne Pharma’s US portfolio; Sun Pharma’s acquisition of Concert Pharma; Bristol Myers Squibb’s expanded Indian footprint and…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
Germany-based pharma and healthcare services group Fresenius has had its share of challenges. After the group’s dialysis division, Fresenius Medical Care (FMC), was hit with a high rate of COVID-19…
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
In light of ongoing geopolitical tension, a globally unfavourable macroeconomic environment and new drug-pricing legislation in the US, at the recent BIO CEO and Investor Conference industry stakeholders evaluated the…
See our Cookie Privacy Policy Here
